SATB2 Expression in Uterine Sarcoma: A Multicenter Retrospective Study
- 13 March 2021
- journal article
- research article
- Published by Wolters Kluwer Health in International Journal of Gynecological Pathology
- Vol. 40 (5) , 487-494
Abstract
Uterine sarcomas represent a clinical challenge because of their difficult diagnosis and the poor prognosis of certain subtypes. The aim of this study was to evaluate the expression of the special AT-rich sequence-binding protein 2 (SATB2) in endometrial stromal sarcoma (ESS) and other types of uterine sarcoma by immunohistochemistry. We studied the expression of SATB2 on 71 full tissue sections of endometrial stromal nodule, low-grade ESS, uterine leiomyomas and leiomyosarcoma, undifferentiated uterine sarcoma, adenosarcoma, and carcinosarcoma samples. Nuclear SATB2 expression was then evaluated in an extended sample set using a tissue microarray, including 78 additional uterine tumor samples. Overall, with a cut-off of ≥10% of tumor cell staining as positive, the nuclear SATB2 score was negative in all endometrial stromal nodule samples (n=10) and positive in 83% of low-grade ESS samples (n=29/35), 40% of undifferentiated uterine sarcoma (n=4/10), 13% of leiomyosarcoma (n=2/16), 14% of adenosarcoma (n=3/22), and 8% carcinosarcoma (n=2/25) samples. Furthermore, in ESS patients, direct comparison of nuclear SATB2 scores with clinicopathologic parameters and other reported biomarkers such as progesterone receptor and estrogen receptor showed that nuclear SATB2 was associated with PR expression and a decreased risk of disease-specific death (odds ratio=0.06, 95% confidence interval=0.04–0.81, P=0.04). Our data suggest that SATB2 could be a marker with relative sensitivity (83%) for distinguishing between endometrial stromal nodule and ESS with potential prognostic value.Keywords
This publication has 27 references indexed in Scilit:
- Uterine Endometrial Stromal Tumors With Limited Infiltration: First Report of a Case Series Indicating Potential for Malignant BehaviorInternational Journal of Gynecological Pathology, 2020
- Uterine Mesenchymal TumorsSurgical Pathology Clinics, 2019
- Recent advances in the histological and molecular classification of endometrial stromal neoplasmsVirchows Archiv, 2018
- Molecular biomarkers for uterine leiomyosarcoma and endometrial stromal sarcomaCancer Science, 2018
- Endometrial stromal sarcomas and related neoplasms: new developments and diagnostic considerationsPathology, 2018
- Practical issues related to uterine pathology: endometrial stromal tumorsLaboratory Investigation, 2016
- Uterine adenosarcomas are mesenchymal neoplasmsThe Journal of Pathology, 2015
- Cyclin D1 as a Diagnostic Immunomarker for Endometrial Stromal Sarcoma With YWHAE-FAM22 RearrangementAmerican Journal of Surgical Pathology, 2012
- Uterine carcinosarcomas (malignant mixed Mullerian tumors) are metaplastic carcinomasInternational Journal of Gynecological Cancer, 2002
- Smooth Muscle, Endometrial Stromal, and Mixed Müllerian Tumors of the UterusLaboratory Investigation, 2000